Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Current Deferred Revenue (2016 - 2024)

Historic Current Deferred Revenue for vTv Therapeutics (VTVT) over the last 10 years, with Q4 2024 value amounting to $18.7 million.

  • vTv Therapeutics' Current Deferred Revenue fell 9.1% to $18.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $18.7 million, marking a year-over-year decrease of 9.1%. This contributed to the annual value of $18.7 million for FY2024, which is 9.1% down from last year.
  • vTv Therapeutics' Current Deferred Revenue amounted to $18.7 million in Q4 2024, which was down 9.1% from $17000.0 recorded in Q3 2024.
  • In the past 5 years, vTv Therapeutics' Current Deferred Revenue ranged from a high of $18.7 million in Q2 2022 and a low of $17000.0 during Q4 2022
  • Its 5-year average for Current Deferred Revenue is $6.6 million, with a median of $35000.0 in 2021.
  • In the last 5 years, vTv Therapeutics' Current Deferred Revenue soared by 10981764.71% in 2023 and then tumbled by 9990.9% in 2024.
  • Over the past 5 years, vTv Therapeutics' Current Deferred Revenue (Quarter) stood at $31000.0 in 2020, then grew by 12.9% to $35000.0 in 2021, then crashed by 51.43% to $17000.0 in 2022, then surged by 109817.65% to $18.7 million in 2023, then decreased by 0.09% to $18.7 million in 2024.
  • Its last three reported values are $18.7 million in Q4 2024, $17000.0 for Q3 2024, and $17000.0 during Q2 2024.